211 related articles for article (PubMed ID: 27100735)
1. The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer.
Nishimura M; Toyoda M; Takenaka K; Imamura Y; Chayahara N; Kiyota N; Mukohara T; Kotake T; Tsuji A; Saito K; Saito Y; Minami H
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1165-70. PubMed ID: 27100735
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis.
Furuse J; Gemma A; Ichikawa W; Okusaka T; Seki A; Ishii T
Jpn J Clin Oncol; 2017 Sep; 47(9):832-839. PubMed ID: 28541474
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Wang Y; Hu GF; Zhang QQ; Tang N; Guo J; Liu LY; Han X; Wang X; Wang ZH
Drug Des Devel Ther; 2016; 10():1961-72. PubMed ID: 27358556
[TBL] [Abstract][Full Text] [Related]
4. Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
Boeck S; Hausmann A; Reibke R; Schulz C; Heinemann V
Anticancer Drugs; 2007 Oct; 18(9):1109-11. PubMed ID: 17704662
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Boeck S; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler T; Fischer von Weikersthal L; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Neugebauer S; Heinemann V
Anticancer Drugs; 2010 Jan; 21(1):94-100. PubMed ID: 19770635
[TBL] [Abstract][Full Text] [Related]
6. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
[TBL] [Abstract][Full Text] [Related]
7. Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma.
Kunkel J; Loddenkemper C; Grozdanovic Z; Schulze K; Schmittel A; Epple HJ; Daum S; Zeitz M
Pancreas; 2011 Jan; 40(1):170-1. PubMed ID: 21160383
[No Abstract] [Full Text] [Related]
8. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
Wang JP; Wu CY; Yeh YC; Shyr YM; Wu YY; Kuo CY; Hung YP; Chen MH; Lee WP; Luo JC; Chao Y; Li CP
Oncotarget; 2015 Jul; 6(20):18162-73. PubMed ID: 26046796
[TBL] [Abstract][Full Text] [Related]
9. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Goldstein D; Hamm J; Figer A; Hecht JR; Gallinger S; Au HJ; Murawa P; Walde D; Wolff RA; Campos D; Lim R; Ding K; Clark G; Voskoglou-Nomikos T; Ptasynski M; Parulekar W;
J Clin Oncol; 2007 May; 25(15):1960-6. PubMed ID: 17452677
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: a retrospective study.
Shinohara A; Ikeda M; Okuyama H; Kobayashi M; Funazaki H; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Ichida Y; Takahashi K; Okusaka T; Saitoh S
Am J Clin Dermatol; 2015 Jun; 16(3):221-9. PubMed ID: 25687689
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E;
Eur J Cancer; 2017 Apr; 75():73-82. PubMed ID: 28222309
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
El-Rayes BF; Philip PA; Sarkar FH; Shields AF; Ferris AM; Hess K; Kaseb AO; Javle MM; Varadhachary GR; Wolff RA; Abbruzzese JL
Invest New Drugs; 2011 Aug; 29(4):694-9. PubMed ID: 20107864
[TBL] [Abstract][Full Text] [Related]
15. [Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience].
Takeda Y; Nakahira S; Katsura Y; Kagawa Y; Okishiro M; Takeno A; Sakisaka H; Suzuki R; Taniguchi H; Egawa C; Kato T; Tamura S
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1884-6. PubMed ID: 24393954
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
Van Cutsem E; Li CP; Nowara E; Aprile G; Moore M; Federowicz I; Van Laethem JL; Hsu C; Tham CK; Stemmer SM; Lipp R; Zeaiter A; Fittipaldo A; Csutor Z; Klughammer B; Meng X; Ciuleanu T
Br J Cancer; 2014 Nov; 111(11):2067-75. PubMed ID: 25247318
[TBL] [Abstract][Full Text] [Related]
17. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.
Feliu J; Borrega P; León A; López-Gómez L; López M; Castro J; Belda-Iniesta C; Barriuso J; Martínez V; González-Barón M
Cancer Chemother Pharmacol; 2011 Jan; 67(1):215-21. PubMed ID: 20927525
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
